Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion
David A Henry, Paul A Carless, Annette J Moxey, Dianne O'Connell, Barrie J Stokes, Dean A Fergusson, Katharine Ker
Cochrane database of systematic reviews (Online) | WILEY | Published : 2011
BACKGROUND: Concerns regarding the safety of transfused blood have led to the development of a range of interventions to minimise blood loss during major surgery. Anti-fibrinolytic drugs are widely used, particularly in cardiac surgery, and previous reviews have found them to be effective in reducing blood loss, the need for transfusion, and the need for re-operation due to continued or recurrent bleeding. In the last few years questions have been raised regarding the comparative performance of the drugs. The safety of the most popular agent, aprotinin, has been challenged, and it was withdrawn from world markets in May 2008 because of concerns that it increased the risk of cardiovascular co..View full abstract
Internal sourcesSpecial purpose grant, Hunter Area Pathology Service, Australia.External sourcesAustralian Health Ministers' Advisory Committee. National Health and Medical Research Council of Australia, Australia.